ZUG, Switzerland

ZUG，瑞士

and

和

BOSTON

波士顿

,

,

Jan. 07, 2025

2025年1月7日

(GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Briggs Morrison, M.D., to its Board of Directors at the Company’s annual general meeting to be held this year..

（环球通讯社）--CRISPR Therapeutics（Nasdaq:CRSP）是一家专注于开发用于严重疾病的转化基因药物的生物制药公司，今天宣布，它提议在今年举行的公司年度股东大会上选举医学博士布里格斯·莫里森（Briggs Morrison）为董事会成员。。

“We are excited to welcome Briggs to our Board of Directors,” said

“我们很高兴欢迎布里格斯加入我们的董事会，”他说

Samarth Kulkarni

萨马斯·库尔卡尼

, Ph.D., Chief Executive Officer and Chairman of the Board of

，博士，首席执行官兼董事会主席

CRISPR Therapeutics

CRISPR治疗学

. “His extensive experience in the pharmaceutical industry and expertise in clinical development will be a tremendous asset as we continue to advance our innovative platform and pipeline, with the goal of developing transformative medicines for patients suffering from serious diseases.”

“随着我们继续推进创新平台和渠道，为患有严重疾病的患者开发变革性药物，他在制药行业的丰富经验和临床开发专业知识将成为巨大的资产。”

“I am thrilled to join such an innovative company at the forefront of gene editing,” said

他说：“我很高兴加入这样一家处于基因编辑前沿的创新公司。”

Briggs Morrison

布里格斯·莫里森

, M.D. “I look forward to collaborating with the Board and the management team to drive CRISPR Therapeutics’ vision forward and contribute to its continued success.”

“我期待着与董事会和管理团队合作，推动CRISPR Therapeutics的愿景向前发展，并为其持续成功做出贡献。”

Dr. Morrison

莫里森博士

currently serves as Chief Executive Officer and as a member of the Board of Directors of Crossbow Therapeutics, Inc. He is trained as a medical oncologist with over 30 years of experience in the pharmaceutical and biotechnology industries, and has held executive roles at Syndax Pharmaceuticals, AstraZeneca PLC, .

目前担任Crossbow Therapeutics，Inc.的首席执行官和董事会成员。他接受过医学肿瘤学家的培训，在制药和生物技术行业拥有30多年的经验，并在AstraZeneca PLC的Syndax Pharmaceuticals担任行政职务。

Pfizer Inc.

辉瑞公司。

, and Merck & Co., Inc. He has overseen the clinical development from Phase 1 through to approval and life cycle management of many approved drugs, including Tagrisso

，以及默克公司。他监督了许多已批准药物的临床开发，从第一阶段到批准和生命周期管理，包括塔格里索

®

®

, Imfinzi

，公式

®

®

and Lynparza

和Lynparza

®

®

.

.

Dr. Morrison

莫里森博士

serves on the Board of Directors of a number of public and private biotechnology companies and is an Entrepreneur Partner at MPM BioImpact. He received his B.S. in Biology from

担任多家公共和私人生物技术公司的董事会成员，是MPM BioImpact的企业家合作伙伴。他于年获得生物学学士学位

Georgetown University

乔治敦大学

and his M.D. from the

还有他的医学博士

University of Connecticut

康涅狄格大学

.

.

About CRISPR Therapeutics

关于CRISPR治疗

Since its inception over a decade ago,

自十多年前成立以来，

CRISPR Therapeutics

CRISPR治疗学

has transformed from a research-stage company advancing programs in the field of gene editing, to a company that celebrated the historic approval of the first-ever CRISPR-based therapy in 2023 and has a diverse portfolio of product candidates across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases.

已经从一家推进基因编辑领域项目的研究阶段公司转变为一家在2023年庆祝首次基于CRISPR的疗法获得历史性批准的公司，并且在包括血红蛋白病，肿瘤学，再生医学，心血管疾病，自身免疫性疾病和罕见疾病在内的广泛疾病领域拥有多种候选产品组合。

.

.

CRISPR Therapeutics

CRISPR治疗学

advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic in 2018 to investigate the treatment of sickle cell disease or transfusion-dependent beta thalassemia, and beginning in late 2023, CASGEVY™ (exagamglogene autotemcel [exa-cel]) was approved in some countries to treat eligible patients with either of those conditions.

2018年，首次将CRISPR/Cas9基因编辑疗法推进临床，以研究镰状细胞病或输血依赖性β地中海贫血的治疗，并从2023年底开始，CASGEVY™（exagamglogene autotemcel[exa cel]）在一些国家被批准用于治疗符合条件的患者。

The Nobel Prize-winning CRISPR science has revolutionized biomedical research and represents a powerful, clinically validated approach with the potential to create a new class of potentially transformative medicines. To accelerate and expand its efforts, .

诺贝尔奖得主CRISPR science彻底改变了生物医学研究，代表了一种强大的临床验证方法，有可能创造一类新的潜在转化药物。加快和扩大努力。

CRISPR Therapeutics

CRISPR治疗学

has established strategic partnerships with leading companies including

与领先公司建立了战略合作伙伴关系，包括

Bayer

拜耳

and Vertex Pharmaceuticals.

和Vertex Pharmaceuticals。

CRISPR Therapeutics AG

CRISPR治疗公司

is headquartered in

总部位于

Zug, Switzerland

瑞士楚格

, with its wholly-owned

，其全资拥有

U.S.

U、 S。

subsidiary,

子公司，

CRISPR Therapeutics, Inc.

CRISPR治疗公司。

, and R&D operations based in

，以及基于

Boston, Massachusetts

马萨诸塞州波士顿

and

和

San Francisco, California

加利福尼亚州旧金山

, and business offices in

，以及位于

London, United Kingdom

英国伦敦

. To learn more, visit

。要了解更多信息，请访问

www.crisprtx.com

www.crisprtx.com

.

.

CRISPR THERAPEUTICS

CRISPR治疗学

®

®

standard word mark and design logo are registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

标准文字标记和设计徽标是CRISPR Therapeutics AG的注册商标。所有其他商标和注册商标均为其各自所有者的财产。

CRISPR Special Note Regarding Forward-Looking Statements

CRISPR关于前瞻性声明的特别说明

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.

本新闻稿中关于非历史事实的声明是1995年《私人证券诉讼改革法案》所指的“前瞻性声明”。由于此类报表存在风险和不确定性，因此实际结果可能与此类前瞻性报表明示或暗示的结果存在重大差异。

Such statements include, but are not limited to, the statements made by Drs. Kulkarni and Morrison in this press release as well as statements regarding any or all of the following: (i) CRISPR Therapeutics’ preclinical studies, clinical trials and pipeline products and programs, including, without limitation, manufacturing capabilities, status of such studies and trials, potential expansion into new indications and expectations regarding data, safety and efficacy generally; (ii) discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics; and (iii) the therapeutic value, development, and commercial potential of gene editing technologies and therapies, including CRISPR/Cas9.

这些声明包括但不限于Kulkarni博士和Morrison博士在本新闻稿中的声明，以及关于以下任何或所有内容的声明：（i）CRISPR Therapeutics的临床前研究，临床试验和管道产品和计划，包括但不限于制造能力，此类研究和试验的现状，潜在的扩展到新的适应症以及对数据，安全性和有效性的预期；（ii）与监管机构讨论CRISPR Therapeutics正在开发的候选产品；（iii）基因编辑技术和疗法（包括CRISPR/Cas9）的治疗价值，发展和商业潜力。

Risks that contribute to the uncertain nature of the forward-looking statements include, without limitation, the risks and uncertainties discussed under the heading “Risk Factors” in its most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S.

导致前瞻性陈述不确定性的风险包括但不限于CRISPR Therapeutics在其最新的年度报告10-K表以及随后向美国提交的任何其他文件中“风险因素”标题下讨论的风险和不确定性。S。

Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. The Company disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release other than to the extent required by law..

证券交易委员会。提醒现有和潜在投资者不要过度依赖这些前瞻性声明，这些声明仅在做出之日起生效。除法律要求外，公司不承担更新或修订本新闻稿中包含的任何前瞻性声明的任何义务或承诺。。

Investor Contact:

投资者联系人：

Susan Kim

苏珊·金

+1-617-307-7503

+1-617-307-7503

susan.kim@crisprtx.com

susan.kim@crisprtx.com

Media Contact:

媒体联系人：

Rachel Eides

瑞秋·艾德斯

+1-617-315-4167

+1-617-315-4167

rachel.eides@crisprtx.com

rachel.eides@crisprtx.com

Source: CRISPR Therapeutics AG

来源：CRISPR Therapeutics AG